Closing the Insights to Action Gap: How Agentic AI Is Reshaping Medical Affairs and Scientific Strategy in Pharma

Author(s): Emily Lewis, MS, HIMSS CPDHTS, CCRP

Abstract

Medical Affairs has spent the better part of two decades trying to reconcile irreconcilable demands: the imperative to move at the speed of science, the obligation to uphold regulatory and compliance standards, and the pressure to demonstrate strategic value beyond commercial support. The arrival of generative artificial intelligence offered partial relief, primarily by accelerating document drafting and literature summarization. The emergence of agentic AI, referring to systems that can plan, execute, and iterate across multi-step workflows with limited human intervention, represents something categorically different. This article examines the strategic implications of agentic AI adoption for Medical Affairs functions within biopharmaceutical organizations. It distinguishes agentic architectures from earlier AI paradigms, anchors the discussion in a five-domain map of where agents are already finding traction across the function, surveys representative use cases within each domain, and identifies the organizational capabilities, governance structures, and risk frameworks that determine whether such deployments succeed or stall. The paper closes with a concrete set of priorities for healthcare leaders tasked with navigating this transition, framed around the recognition that agentic systems do not simply augment the workforce but reconstitute how scientific engagement itself is designed, measured, and delivered.